Bristol Myers Squibb (BMY) Divestments (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Divestments for 18 consecutive years, with $209.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Divestments fell 22.59% year-over-year to $209.0 million in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 2.0% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, down 2.55% from the prior year.
• Divestments was $209.0 million for Q2 2026 at Bristol Myers Squibb, down from $312.0 million in the prior quarter.
• Over five years, Divestments peaked at $490.0 million in Q4 2022 and troughed at $192.0 million in Q2 2022.
• A 5-year average of $272.5 million and a median of $251.0 million in 2023 frame the typical range for Divestments.
• Across the five-year window, Divestments surged 175.28% in 2022 and sank 50.82% in 2023, its largest moves.
• Over 5 years, Divestments stood at $490.0 million in 2022, then slumped by 50.82% to $241.0 million in 2023, then soared by 38.17% to $333.0 million in 2024, then slipped by 16.22% to $279.0 million in 2025, then declined by 25.09% to $209.0 million in 2026.
• The last three Divestments figures came in at $209.0 million (Q2 2026), $312.0 million (Q1 2026), and $279.0 million (Q4 2025), per Business Quant data.